About Immatics: The PRAME Leader

Female scientist viewing a sample in the lab

Since its foundation, Immatics has been relentlessly focused on building its scientific approach from the ground up to develop and deliver novel PRAME immunotherapies for patients with cancer.

Today, Immatics is the global leader in the precision targeting of PRAME, a target expressed in more than 50 cancers, and has the broadest PRAME franchise with the most PRAME indications and modalities.

Quick facts

PRAME

Lead target across Immatics' franchise

700

Team members in Tuebingen, Munich and Houston, Texas

Global sites

Clinical programs

Therapeutic modalities, cell therapies and bispecifics, in clinical development

Technology platforms for target and TCR discovery

A transatlantic organization

Immatics operates as a transatlantic organization with the team spanning from Tuebingen and Munich, Germany to Houston, Texas. The long-term integration of the European and US sites also brings the advantage that Immatics has built a highly functioning team across two continents with access to two important markets for medical innovation.

‍

Since its foundation in 2000 as a spin-out from H.G. Rammensee’s laboratory at University of Tuebingen, Germany, Immatics has revolutionized the identification of tumor-associated pHLA targets, which are recognized by T cells. Identifying true cancer targets that are presented on tumor tissue but not on healthy cells and the subsequent discovery, selection, and engineering of a therapeutic TCR are central to Immatics’ mission: Making a meaningful impact on the lives of patients with cancer.

‍

In 2015, Immatics and MD Anderson Cancer Center launched Immatics US, Inc. in Houston, Texas, as a joint venture to develop transformative Adoptive Cell Therapies.